Product Program year 2025 Source: CMS Open Payments

Pediarix

Biological Vaccines

NDC 58160-811-52

Open in the dashboard

General payments

$899,275

51,308 payments

Research payments

$334,486

72 payments

Through program year 2025, $899,275 in general payments and $334,486 in research payments were reported against Pediarix (Vaccines).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

9 rows
Year Kind Amount Payments
2025 General $82,105 4,536
2024 General $85,646 4,798
2023 General $164,732 9,077
2022 General $178,101 10,262
2021 General $144,691 8,583
2020 General $99,822 5,585
2020 Research $73,077 6
2019 General $144,179 8,467
2019 Research $261,409 66

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $899,275 51,308 payments
Top recipients General payments · program year 2025
  1. Matthew Keysor Pediatrics · Colorado Springs, CO $138 <1% · 10 payments
  2. Narinder Bala Pediatrics · Fresno, CA $135 <1% · 9 payments
  3. Jennifer Quillin Adolescent Medicine · Hazel Green, AL $110 <1% · 6 payments
  4. Nicholas Mulhearn Adolescent Medicine · Meadville, PA $105 <1% · 5 payments
  5. Stacey Ferguson Physician Assistant · Pittsburgh, PA $105 <1% · 5 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Pediatrics $42,285 53% · 1,653 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $8,896 11% · 399 practitioners
  3. Nurse Practitioner, Pediatrics Nurse Practitioner $7,319 9% · 311 practitioners
  4. Family Medicine $5,752 7% · 282 practitioners
  5. Physician Assistant $4,615 6% · 181 practitioners

The top 5 of 65 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $7,216 9% · 258 recipients
  2. Texas $7,017 9% · 303 recipients
  3. New Jersey $5,966 7% · 217 recipients
  4. Florida $5,564 7% · 238 recipients
  5. Tennessee $4,924 6% · 215 recipients

The top 5 of 45 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

41

Prescriptions dispensed, refills included

Drug cost

$4,349

Paid at the pharmacy, in all

Prescribers

3

With 11 or more claims of it

Medicare Part D drugs matched to PEDIARIX, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Pediarix Hep B Vaccine/Dp(A)t-Polio/Pf Same name 3 41 $4,349

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

3 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Chaitanya Iragavarapu Hematology-Oncology KY 16 $1,730 None on record
Syed Abutalib Hematology-Oncology WI 13 $1,347 None on record
Syed Haider Hematology-Oncology WI 12 $1,271 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

51,308 general · 72 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record